EAACI Congress 2023
BackFlash talks on immunodeficiencies and autoimmunity
Friday 09 Jun, 13:15 PM -
14:45 PM CEST
Hall Y 11+12
Flash Talks
13:15
Comorbidities in Angioedema due to C1-inhibitor deficiency: an Italian survey
13:22
Immunoglobulin replacement therapy: unexpected preference for intravenous route in a Portuguese adult cohort
13:29
Long-Term Effectiveness and Safety of Lanadelumab Regardless of Baseline Attack Rate: Pooled Analysis of the ENABLE and EMPOWER Studies
13:36
An observational retrospective study on vaccinations in immunocompromised patients
13:43
Quality of Life During Lanadelumab Treatment in Patients with Hereditary Angioedema: 24-Month Results From the ENABLE Study
13:50
Real-World Effectiveness and Safety of Lanadelumab for Prophylaxis of Hereditary Angioedema Attacks: 2-Year Interim Results From the ENABLE Study
13:57
Relationship Between Autoimmune Manifestations and Genetic Disorders in Patients with PID: A Single Center 10-Year Experience
14:04
Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults
14:11
Chronic lung disease, age, and IgA influence perturbation of respiratory microbial ecosystems in Common Variable Immunodeficiency
14:18
Initial Results from a Phase 1 Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Subjects Followed for at Least 3 Months
14:25
Design of ALPHA-STAR, a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Active Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or
14:32
GASTROINTESTINAL SYSTEM INVOLVEMENT in PATIENTS WITH PRIMARY IMMUNE DEFICIENCY
14:39
Treatment of angioedema due to acquired C1-inhibitor deficiency with PHA121, a novel oral bradykinin B2 receptor antagonist
